{"id":"mifl-bevacizumab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Hypertension"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T17:49:35.875181","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"miFL works by binding to bevacizumab, preventing it from inhibiting VEGF-A. This allows VEGF-A to promote angiogenesis, which is essential for tumor growth and metastasis. By inhibiting bevacizumab, miFL may help to improve treatment outcomes in certain types of cancer.","oneSentence":"miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:24.955Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic colorectal cancer"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT00101686","phase":"PHASE3","title":"Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Colorectal Neoplasms","enrollment":547}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"miFL + bevacizumab","genericName":"miFL + bevacizumab","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}